Side-by-side comparison of AI visibility scores, market position, and capabilities
Tempe AZ consumer cybersecurity (NASDAQ: GEN) ~$3.8B FY2024 revenue; Norton+Avast+LifeLock 500M+ users, NortonLifeLock-Avast merger 2022, identity protection growth competing with McAfee and Aura.
Gen Digital Inc. is a Tempe, Arizona-based consumer cybersecurity company — publicly traded on the NASDAQ (NASDAQ: GEN) as an S&P 500 Information Technology component — providing digital safety products and services for individuals and families through a portfolio of brands including Norton (antivirus, VPN, identity protection), Avast (security for PC and mobile), LifeLock (identity theft protection and dark web monitoring), Avira (European consumer security), and CCleaner (device optimization) through approximately 4,000 employees serving 500+ million users globally. Gen Digital was formed in September 2022 through the merger of NortonLifeLock and Avast (acquired for $8.6 billion), combining two of the three largest global consumer cybersecurity brands — Norton's North American household name recognition and LifeLock's identity theft insurance and recovery services with Avast's European and Asian user base. In fiscal year 2024 (ending March 2024), Gen Digital reported revenues of approximately $3.8 billion with adjusted EPS growth as the company integrated the Avast acquisition, captured cross-sell opportunities (marketing Norton 360 with LifeLock to Avast's 40+ million paying subscribers), and managed the post-acquisition deleveraging of the $6+ billion debt load from the Avast acquisition financing. CEO Vincent Pilette leads Gen Digital's strategy of evolving consumer cybersecurity from device protection (antivirus for Windows PCs) to comprehensive digital life safety: identity protection, financial fraud monitoring, VPN privacy, parental controls, and dark web surveillance — a broader Total Digital Safety positioning that expands the addressable market beyond the traditional antivirus software category.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.